Belimumab use in paediatric-onset systemic lupus erythematosus: a status report in France from a retrospective multicentre descriptive study
Authors' conclusion
This retrospective, multicentre study found that belimumab, primarily administered intravenously, was effective for articular involvement and had a corticosteroid-sparing effect in jSLE, with a favourable safety profile. Its efficacy was limited for cutaneous, renal and haematological manifestations.
Study context
- Population
- Patients with juvenile-onset SLE (2019 EULAR/ACR criteria) starting belimumab before age 18, France
- Participants
- 21 patients
- Exposure
- Belimumab at 6 months vs baseline
- Outcome
- Real-world use, efficacy and safety of belimumab
- Follow-up
- 6 months
Main finding
As reported in the abstract
Efficacy at 6 months
Corticosteroid use, baseline vs 6 months (trend towards lower)
0.53 vs 0.15 mg/kg/day
Proportion achieving low disease activity status, baseline vs 6 months
6.3% vs 37.5%
Complete resolution of articular manifestations
77.8%
Observational data: associations, not effects.
Further findings
Use of belimumab
- Intravenous belimumab
- 90.5%
- Indication: articular manifestations
- 66.7%
- Indication: cutaneous manifestations
- 23.8%
Safety
Tolerability
- Discontinuation due to psychiatric symptoms
- 1
- Overall well tolerated
Original publication
Belimumab use in paediatric-onset systemic lupus erythematosus: a status report in France from a retrospective multicentre descriptive study. Rheumatology (Oxford). Published 26 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →